You are here:

Archived: umeclidinium/vilanterol (Anoro®)

Advice

following a full submission:

umeclidinium/vilanterol (Anoro®) is not recommended for use within NHS Scotland.

Indication under review: As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Three randomised controlled studies demonstrated that after 24 weeks of treatment, umeclidinium/vilanterol significantly improved lung function compared with an inhaled long-acting antimuscarinic in patients with moderate to very severe COPD.  However there was no difference between treatments in dyspnoea or health status.

The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC. 

The licence holder has indicated their intention to resubmit.

Drug Details

Drug Name: umeclidinium/vilanterol (Anoro®)
SMC Drug ID: 978/14
Manufacturer: GlaxoSmithKline UK Ltd
Indication: As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 11 August 2014

Current Advice

Resubmission 9 February 2015

Back